Best Peptides for Anti-Aging & Longevity: Ranked by Evidence (2026)
Longevity peptides range from cosmetic skin ingredients to experimental mitochondrial compounds. Only a few, such as SS-31 (elamipretide) for Barth syndrome, have an FDA-approved product, and none is approved to slow aging. The ordering below is by strength of evidence and regulatory status, not by brand.
The ranking
| Compound | FDA status | Evidence level | PubMed papers | Tagged trials |
|---|---|---|---|---|
| SS-31 | FDA-approved | FDA-approved product | 206 | 15 |
| Glutathione | Not an FDA-approved standalone drug | Preclinical or minimal | 180,033 | 2,785 |
| NAD+ | Not an FDA-approved drug | Preclinical or minimal | 17,148 | 141 |
| Humanin | Not approved (research only) | Preclinical or minimal | 549 | 8 |
| MOTS-c | Not approved (research only) | Preclinical or minimal | 259 | 5 |
| GHK-Cu | Not approved (research only) | Preclinical or minimal | 83 | 1 |
| Epithalon | Not approved (research only) | Preclinical or minimal | 64 | 1 |
| Argireline | Not approved (research only) | Preclinical or minimal | 8 | 1 |
| Rigin | Not approved (research only) | Preclinical or minimal | 6 | 1 |
| Syn-Coll | Not approved (research only) | Preclinical or minimal | 4 | 1 |
| Palmitoyl dipeptide-6 | Not approved (research only) | Preclinical or minimal | 1 | 1 |
| Melanostatin DM | Not approved (research only) | Preclinical or minimal | 60 | 0 |
| Copper peptides | Not approved (research only) | Preclinical or minimal | 57 | 0 |
| FOXO4-DRI | Not approved (research only) | Preclinical or minimal | 19 | 0 |
| Vialox | Not approved (research only) | Preclinical or minimal | 6 | 0 |
| Matrixyl | Not approved (research only) | Preclinical or minimal | 5 | 0 |
| Leuphasyl | Not approved (research only) | Preclinical or minimal | 4 | 0 |
| Palmitoyl tripeptide-1 | Not approved (research only) | Preclinical or minimal | 3 | 0 |
| AHK-Cu | Not approved (research only) | Preclinical or minimal | 1 | 0 |
| SNAP-8 | Not approved (research only) | Preclinical or minimal | 0 | 0 |
| Tripeptide-3 | Not approved (research only) | Preclinical or minimal | — | — |
Why each of the top 6 ranks where it does
1. SS-31
FDA-approved product: FDA-approved; FORZINITY. PubMed lists 206 records (15 tagged as clinical trials) and ClinicalTrials.gov 21 registered studies. A recent trial report: Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. (Orphanet J Rare Dis, 2024). Registered study: NCT07275424 (phase2), recruiting.
2. Glutathione
Preclinical or minimal: Not an FDA-approved standalone drug. PubMed lists 180,033 records (2,785 tagged as clinical trials) and ClinicalTrials.gov 272 registered studies. A recent review: Glutathione as a skin-lightening agent and in melasma: a systematic review. (Int J Dermatol, 2025). Registered study: NCT06345950 (na), completed.
3. NAD+
Preclinical or minimal: Not an FDA-approved drug. PubMed lists 17,148 records (141 tagged as clinical trials) and ClinicalTrials.gov 268 registered studies. A recent review: The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential. (Genes Dis, 2022). Registered study: NCT06950463 (na), recruiting.
4. Humanin
Preclinical or minimal: Not approved (research only). PubMed lists 549 records (8 tagged as clinical trials) and ClinicalTrials.gov 3 registered studies. A recent trial report: Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer's disease. (Alzheimers Res Ther, 2023). Registered study: NCT07678073 (na), recruiting.
5. MOTS-c
Preclinical or minimal: Not approved (research only). PubMed lists 259 records (5 tagged as clinical trials) and ClinicalTrials.gov 5 registered studies. A recent review: MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. (Front Endocrinol (Lausanne), 2023). Registered study: NCT07678073 (na), recruiting.
6. GHK-Cu
Preclinical or minimal: Not approved (research only). PubMed lists 83 records (1 tagged as clinical trials) and ClinicalTrials.gov 3 registered studies. A recent review: Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. (Am J Sports Med, 2026). Registered study: NCT07706361 (na), not yet recruiting.
With an FDA-approved product
- SS-31 — FDA-approved; FORZINITY
Where to go next
Overview of the category: Anti-Aging & Longevity peptide therapy. Prescribers: clinic directory. Seller facts and prices: vendor directory and price tracker.
Frequently asked questions
Which anti-aging & longevity peptides are FDA-approved?
SS-31 has an FDA-approved product, each for a specific labeled indication — not necessarily for anti-aging & longevity in general.
How is this list ordered?
By regulatory status first (FDA-approved, previously approved, in clinical trials or approved abroad, preclinical), then by the number of PubMed-indexed clinical-trial papers. It ranks evidence, not sellers, and no company can pay to change the order.
Can I buy these online?
FDA-approved drugs require a prescription. Products sold as "research peptides" are labeled not for human use and are not FDA-approved; see each compound page for its status and our vendor directory for documented facts about sellers.